ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 047,60
-0,90%
Dow Jones
41 911,71
-2,08%
DAX
22 620,95
-1,65%
Brent Oil
69,05
0,01%
Bitcoin
80 057,33
2,02%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Intellia Therapeutics Inc (NTLA) Cours

Intellia Therapeutics Inc

Intellia Therapeutics Inc (NTLA)

NASDAQ
9,46
-0,89
(-8,60%)
Fermé 11 Mars 9:00PM
Retardé de 15 minutes
9,40
-0,06
(-0,63%)
Après les heures de négociation: 12:55AM
Retardé de 15 minutes

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Statistiques et détails clés

Dernier
9,40
Prix Achat
9,12
Prix Vente
9,75
Volume échangé
3 604 244
9,4201 Fourchette du Jour 10,10
8,30 Plage de 52 semaines 31,10
Cap du marché
973,064M
Clôture Veille
10,35
Ouverture
9,995
Dernière Transaction
25
@
9.74
Dernière heure de transaction
Volume financier
US$ 34 931 393
VWAP
9,6917
Volume moyen (3 m)
3 121 085
Actions en circulation
103 517 460
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-2,04
Bénéfice par action (BPA)
-4,65
Chiffre d'affairess
36,28M
Bénéfice net
-481,19M

À propos de Intellia Therapeutics Inc

Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering speci... Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis. Show more

Secteur
In Vitro,in Vivo Diagnostics
Industrie
In Vitro,in Vivo Diagnostics
Site Web
www.intelliatx.com
Siège social
Wilmington, Delaware, USA
Fondé
-
Intellia Therapeutics Inc est coté dans le secteur In Vitro,in Vivo Diagnostics de la NASDAQ avec le ticker NTLA. Le dernier cours de clôture d'Intellia Therapeutics était de US$10,35. Au cours de la dernière année, les actions de Intellia Therapeutics ont été négociées dans une fourchette de prix de US$ 8,30 à US$ 31,10.

Intellia Therapeutics compte actuellement 103 517 460 actions en circulation. La capitalisation boursière d'Intellia Therapeutics est de US$1,07 milliard. Intellia Therapeutics a un ratio cours/bénéfice (ratio PE) de -2.04.

Flux d'options Intellia Therapeutics (NTLA)

Voir le flux d'options complet

Flux global

Haussier

Prime nette

97k

Calls / Puts

100,00%

Ach. / Vent.

100,00%

OTM / ITM

0,00%

Sweeps Ratio

0,00%

NTLA Dernières nouvelles

Plus de nouvelles

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
04 Mars 2025
NTLA (-8,60%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
04 Mars 2025
NTLA (-8,60%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
04 Mars 2025
NTLA (-8,60%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
04 Mars 2025
NTLA (-8,60%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
04 Mars 2025
NTLA (-8,60%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
04 Mars 2025
NTLA (-8,60%)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.7112-7.0337843183810.111210.688.338370009.58132776CS
4-0.49-4.954499494449.8912.848.3372200810.64451506CS
12-3.46-26.905132192812.8613.798.3312108510.82040728CS
26-10.46-52.668680765419.8623.768.3269855813.71058806CS
52-20.35-68.403361344529.7531.18.3205390517.38989938CS
156-55.09-85.424096759264.4978.588.3147471530.82413957CS
260-3.68-28.134556574913.08202.738.3137520748.16180264CS

NTLA - Frequently Asked Questions (FAQ)

What is the current Intellia Therapeutics share price?
The current share price of Intellia Therapeutics is US$ 9,40
How many Intellia Therapeutics shares are in issue?
Intellia Therapeutics has 103 517 460 shares in issue
What is the market cap of Intellia Therapeutics?
The market capitalisation of Intellia Therapeutics is USD 1,07B
What is the 1 year trading range for Intellia Therapeutics share price?
Intellia Therapeutics has traded in the range of US$ 8,30 to US$ 31,10 during the past year
What is the PE ratio of Intellia Therapeutics?
The price to earnings ratio of Intellia Therapeutics is -2,04
What is the cash to sales ratio of Intellia Therapeutics?
The cash to sales ratio of Intellia Therapeutics is 27
What is the reporting currency for Intellia Therapeutics?
Intellia Therapeutics reports financial results in USD
What is the latest annual turnover for Intellia Therapeutics?
The latest annual turnover of Intellia Therapeutics is USD 36,28M
What is the latest annual profit for Intellia Therapeutics?
The latest annual profit of Intellia Therapeutics is USD -481,19M
What is the registered address of Intellia Therapeutics?
The registered address for Intellia Therapeutics is CORPORATION TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
What is the Intellia Therapeutics website address?
The website address for Intellia Therapeutics is www.intelliatx.com
Which industry sector does Intellia Therapeutics operate in?
Intellia Therapeutics operates in the IN VITRO,IN VIVO DIAGNOSTICS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
CAPSCapstone Holding Corp
US$ 3,11
(1 144,00%)
74,5k
HMRHeidmar Maritime Holdings Corporation
US$ 2,5599
(69,53%)
37,58M
RDFNRedfin Corporation
US$ 9,76
(67,70%)
92,54M
CKPTCheckpoint Therapeutics Inc
US$ 3,9895
(61,52%)
60,92M
STSSSharps Technology Inc
US$ 0,4399
(48,26%)
591,61M
SXTCChina SXT Pharmaceuticals Inc
US$ 2,78
(-35,54%)
162,75k
PCLAPicoCELA Inc
US$ 0,8499
(-35,12%)
866,61k
CONLGraniteShares ETF Trust GraniteShares
US$ 15,685
(-34,86%)
8,71M
MSTXTidal Trust II Defiance Daily Target 2x Long MSTR ETF
US$ 19,22
(-32,95%)
24,19M
JVACoffee Holdings Co
US$ 6,53
(-31,77%)
988,94k
STSSSharps Technology Inc
US$ 0,4399
(48,26%)
591,61M
NVDANVIDIA Corporation
US$ 106,98
(-5,07%)
364,12M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 7,3701
(-30,86%)
258,67M
TSLATesla Inc
US$ 222,15
(-15,43%)
188,57M
TQQQProShares UltraPro QQQ
US$ 59,81
(-11,27%)
155,18M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
NTLA
Intellia Therapeutics
BIT
NSCIT0054469
Kripton Spe
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces